Mayor Zohran Mamdani confirms the rising human toll from the prolonged freeze, with hypothermia suspected in most cases as the city battles historically low temperatures.
President Trump urges immediate House passage of a bipartisan spending deal to end the government shutdown, facing resistance from both progressive Democrats and his own party's right flank over immigration enforcement terms.
The Bureau of Labor Statistics has postponed the release of January's crucial employment data due to a partial government shutdown, leaving markets and policymakers in the dark as a funding impasse in Congress continues.
As the energy sector leads the market in early 2026, ConocoPhillips and Kinder Morgan emerge as compelling picks for investors seeking reliable, growing dividends backed by strong fundamentals and strategic positioning.
Oracle's ambitious plan to raise up to $50 billion for AI infrastructure has triggered volatile swings in its share price, reflecting broader investor anxiety over the massive capital demands of the artificial intelligence arms race.
While Broadcom rides a massive wave of AI demand, investor concerns over shrinking profitability have triggered a significant pullback in its shares, presenting a classic growth-versus-margin dilemma.
A 25-year-old Johnstown woman faces 18 felony counts, including arson endangering lives, after investigators say she intentionally set a duplex fire that forced residents to leap from second-story windows to escape.
TD Cowen and H.C. Wainwright have raised price targets on KalVista Pharmaceuticals, expressing confidence in its oral hereditary angioedema treatment ahead of the company's fourth-quarter financial results.
Bernstein analyst lifts ASML's price target to $1,911, citing a buying opportunity after recent pullback. The chip equipment giant's record Q4 orders and updated guidance signal confidence in the AI-driven semiconductor upcycle.
Oppenheimer upgrades Relay Therapeutics (RLAY) to Outperform, citing the strength of its mutant-selective inhibitor pipeline and upcoming catalysts in the breast cancer treatment arena.
Fifth Third Bancorp has finalized its acquisition of Comerica Incorporated, a move that consolidates the Midwest banking landscape and creates the nation's ninth-largest bank with nearly $300 billion in assets.
New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.
While many AI stocks soared in 2025, Salesforce shares faced significant headwinds. Despite a challenging year, the cloud software giant's robust fundamentals and reasonable valuation suggest it may be poised for a recovery.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
Abbott Laboratories moves to acquire cancer-testing leader Exact Sciences in a landmark deal, signaling a strategic shift toward high-growth diagnostics while simultaneously restructuring its challenged Nutrition business.
CNBC's Jim Cramer lauds Salesforce's operational strength, yet the stock, alongside peer ServiceNow, faces persistent 'multiple compression' as Wall Street reevaluates growth expectations for mature software leaders.
CNBC's Jim Cramer reaffirms his bullish stance on NVIDIA, calling the chipmaker the dominant force in the rapidly evolving artificial intelligence landscape, while analysts debate the sustainability of its market position.
CNBC's Jim Cramer positions Alphabet as the potential 'only winner in AI,' suggesting its upcoming earnings may show it generating more revenue from AI than rival Meta Platforms.
CNBC's Jim Cramer highlights a dramatic turnaround for Meta Platforms, arguing its heavy investment in artificial intelligence is fundamentally reshaping the company's trajectory and market perception.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
